10-K: OneMedNet Reports Full Year 2024 Results, Faces Going Concern Uncertainty

OneMedNet Corporation reports a net loss of $10.1 million for 2024 and expresses substantial doubt about its ability to continue as a going concern.

Summary

• OneMedNet Corporation experienced a net loss of $10.1 million in 2024, compared to a net loss of $33.8 million in 2023.
• The company's accumulated deficit as of December 31, 2024, was approximately $101.6 million.
• Revenue decreased by 37% year-over-year, with subscription revenue declining by 60% and web imaging revenue increasing by 104%.
• The company's independent auditor has expressed substantial doubt about its ability to continue as a going concern.
• OneMedNet is pursuing additional financing through equity and debt arrangements.
• The company is focusing on its iRWDTM service offering and discontinuing the BEAM platform.
• The company is subject to extensive government regulation and faces risks related to data privacy and security.
• OneMedNet is an emerging growth company and may take advantage of reduced reporting requirements.
• The company has identified material weaknesses in its internal control over financial reporting.
• The company is subject to risks related to holding bitcoin, the price of which has been, and will likely continue to be, highly volatile.

Sentiment

Score: 3

Explanation: The document presents a concerning financial situation with declining revenue, significant losses, and an auditor's going concern warning, offset by some positive trends in web imaging revenue and cost control. The need for additional financing and material weaknesses in internal controls further contribute to a negative outlook.

Positives

• Net loss decreased from $33.8 million in 2023 to $10.1 million in 2024.
• Web imaging revenue increased by 104% to $292 thousand in 2024.
• The company is focusing on its iRWDTM service offering, which has potential for growth.
• The company is pursuing additional financing through equity and debt arrangements.

Negatives

• The company experienced a net loss of $10.1 million in 2024.
• Total revenue decreased by 37% to $643 thousand in 2024.
• Subscription revenue decreased by 60% to $351 thousand in 2024.
• The company's auditor has expressed substantial doubt about its ability to continue as a going concern.
• The company has identified material weaknesses in its internal control over financial reporting.

Risks

• The company may never achieve profitability.
• The company may be unable to raise additional capital in sufficient amounts or on acceptable terms.
• The company may be unable to reverse the recent decline in revenue and resume growing revenue.
• The company may be unable to adequately protect or expand its intellectual property.
• The company may face increased costs, penalties, and a loss of business if it fails to comply with healthcare industry regulations.
• The company's collection, use, and disclosure of personal information is subject to privacy and security regulations.
• The company's operations could be damaged or adversely affected as a result of natural disasters and other catastrophic events.
• The company is subject to risks related to holding bitcoin, the price of which has been, and will likely continue to be, highly volatile.
• The company may be unable to maintain listing of its securities on Nasdaq or any stock exchange.
• The company's management has limited experience in operating a public company.
• The company has identified material weaknesses in its internal control over financial reporting.
• The company may not be able to raise additional capital on attractive terms, if at all, and any additional capital it does raise through issuances of equity securities could be dilutive to stockholders.

Future Outlook

The company intends to continue funding its operations through equity and debt financing arrangements and aims to achieve profitable operations.

Industry Context

The Real World Evidence solutions market is expected to grow at a CAGR of 8.4% from 2024 to 2030, driven by rising demand for enhanced Real World Evidence capabilities within the life science industry.

Comparison to Industry Standards

• The global Real World Evidence solutions market size was estimated at USD $2.6 billion in 2023 and is expected to grow at a compound annual growth rate (CAGR) of 8.4% from 2024 to 2030.
• According to Coherent Market Insights, the global Real World Data market is estimated to be valued at $7.51 billion in 2024 and is expected to exhibit a CAGR of 9.1% during the forecast period (2024-2031).

Management Changes

Related Party Transactions

• The company entered into PIPE Notes and Warrants with related parties.
• The company entered into Convertible Promissory Notes and Warrants with related parties.
• The company entered into Shareholder Loans with related parties.
• The company assumed Data Knights loan extensions to related parties.

Stakeholder Impact

• Shareholders may experience dilution due to potential equity issuances.
• Employees face uncertainty due to the company's going concern status.
• Customers may be impacted by the company's strategic shift and potential service disruptions.
• Creditors face increased risk due to the company's financial difficulties.

Next Steps

• The company is evaluating potential actions to regain compliance with all applicable requirements for continued listing on the Nasdaq Capital Market.
• The company intends to continue funding its operations through equity and debt financing arrangements.
• The company is in the process of remediating the identified material weaknesses in its internal controls.

Key Dates

Keywords

Real World Data, Real World Evidence, iRWDTM, healthcare, imaging, OneMedNet, revenue, loss, financials, bitcoin, warrants